Regencell Bioscience Holdings experienced dramatic stock price fluctuations, characterized by massive historical peaks followed by sharp, prolonged downward corrections that brought its valuation significantly below its fifty-day and two-hundred-day moving averages. The equity became well-known in micro-cap trading circles for sporadic, extreme price spikes driven by low public floats and apparent short-squeeze dynamics, interspersed with heavy selling phases. Corporate capital-raising activities, registered direct equity offerings, and investor class-action lawsuits further amplified the turbulent trading history, keeping institutional ownership low and retail speculative interest high.